{
  "docId": "019dd923-622c-750b-8b9a-21918ac10c17",
  "docSlug": "f3db2294dcf9",
  "documentTitle": "Harmony Biosciences (HRMY)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2023-03-28 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 86,
  "pageCount": 366,
  "prevPage": 85,
  "nextPage": 87,
  "slideType": "quote_slide",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide uses a Q&A format to frame the failure as a known, expected outcome rather than a surprise, highlighting the difficulty of the H3 class.",
  "elementsJson": [
    "paragraph",
    "quote_block"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-21918ac10c17/86",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17#slide-86",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Abbott spent almost a decade trying to solve the pharmacokinetic and bioavailability issues in the program and couldn't, illustrating the severity of the problems in the H3 class – “this was no surprise to anyone.”",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64d0-7099-9ccf-93349e7f31d3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.86,
        "x": 0.07,
        "y": 0.29
      },
      "kind": "paragraph",
      "text": "Spent almost a decade on the program and couldn't solve the bioavailability and PK issues which were “no surprise”\nQ: “So, you just dosed 12 people one time in the clinic. You saw the massive variability, and you were like - this thing is dead on arrival?\nA: “Exactly. So, it's four doses, and you take three patients, three healthy volunteers, and then if there is no toxicity, the next three was the highest dose and so on and so on until you reach your 12.”\nQ: “So, you gave 3 to 90, and what were the middle doses?”\nA: “We went up to 90, so we went, from 3 milligrams, 15, 30, 60, and 90.”\nQ: “And you just observed 1% bioavailability in each of those doses, essentially?”\nA: “Yeah, that was the most important for us to really understand how the drug is distributed and released in the body.”\nQ: “And what was your personal reaction? The reaction at Abbott? Were you guys like, wow, this thing is a disaster? How was this program viewed?”\nA: “No, I don't think, because we have the experience, as I said, from betahistine And we had a lot of discussions ourselves about do we want to repeat some of the PK and the Phase 2 of the dosage finding of betahistine, which is our H1 receptor in vertigo. And we knew that for a long time. This was no surprise for anybody. The disappointment was that we were trying to fix the 2012 problem until 2017-2018, and we didn't manage to fix it. So, the disappointment was okay. This is R&D life, as usual.”\nQ: “You said you guys spent six years on the program that basically failed?”\nA: “Correct, but it's good it was killed at this stage because at that stage the spending is very limited.” – Senior pharmaceutical executive/scientist, previously at Abbott and now at another major pharma company",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c273cd27-613a-4d24-87aa-2cf3c45381a3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“this was no surprise to anyone.” — Senior pharmaceutical executive/scientist, previously at Abbott and now at another major pharma company",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64d0-7099-9ccf-948a59ec8392",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.3,
        "x": 0.07,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d3380b0f-77cf-4688-b05e-a5a8776f953a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "title",
      "text": "Abbott spent almost a decade trying to solve the pharmacokinetic and bioavailability issues in the program and couldn't, illustrating the severity of the problems in the H3 class – “this was no surprise to anyone.” He indicated that even though they escalated doses from 3mg all the way to 90mg – similar dosages to those in the pitolisant studies - they still observed almost no bioavailability.",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8934b1e9-10bc-48be-a4b4-1d630e9eb323",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}